Cargando…

Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors

Some patients with cancer treated with programmed death 1 (PD-1) inhibitors experience immune-related severe adverse events (ir-SAEs), however, predictors are limited. The objective was to identify clinicopathologic features that may be associated with a higher ir-SAE risk. This was a nested case-co...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lijun, Li, Yang, Jiang, Ning, Song, Xue, Xu, Jianhua, Zhu, Xiangzhi, Chen, Cheng, Kong, Cheng, Wang, Xiaohua, Zong, Dan, Li, Luan, Han, Cen, Yin, Li, He, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986630/
https://www.ncbi.nlm.nih.gov/pubmed/35250004
http://dx.doi.org/10.1097/CJI.0000000000000415
_version_ 1784682571758567424
author Zhao, Lijun
Li, Yang
Jiang, Ning
Song, Xue
Xu, Jianhua
Zhu, Xiangzhi
Chen, Cheng
Kong, Cheng
Wang, Xiaohua
Zong, Dan
Li, Luan
Han, Cen
Yin, Li
He, Xia
author_facet Zhao, Lijun
Li, Yang
Jiang, Ning
Song, Xue
Xu, Jianhua
Zhu, Xiangzhi
Chen, Cheng
Kong, Cheng
Wang, Xiaohua
Zong, Dan
Li, Luan
Han, Cen
Yin, Li
He, Xia
author_sort Zhao, Lijun
collection PubMed
description Some patients with cancer treated with programmed death 1 (PD-1) inhibitors experience immune-related severe adverse events (ir-SAEs), however, predictors are limited. The objective was to identify clinicopathologic features that may be associated with a higher ir-SAE risk. This was a nested case-control study. After screening a total of 832 PD-1 inhibitor-treated patients, we identified 42 ir-SAE cases. According to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, ir-SAEs were defined as grade ≥3 toxic effects associated with immunotherapy. A total of 126 controls were matched. The crude and adjusted risks of ir-SAEs were estimated by odds ratio (ORs) and 95% CIs using multivariate logistic regression models. Baseline neutrophil-to-lymphocyte ratio (NLR) [per SD increment-adjusted (aOR): 1.16], lactate dehydrogenase (LDH) ≥245 U/L (aOR: 2.39), and antibiotic exposure (aOR: 4.39) were associated with a higher risk of ir-SAEs. When NLR was categorized in 3 groups, significantly higher risks of ir-SAEs (aOR: 4.95) were found in participants in group 3 (>6) than in those in group 1 (<3). Furthermore, NLR (per SD increment-adjusted hazard ratio:1.08) were also significantly associated with shorter overall survival (OS). Baseline LDH ≥245 U/L and antibiotic exposure were no significant association with OS. In conclusion, ir-SAEs were associated between baseline NLR, LDH ≥245 U/L and antibiotic exposure. Lower NLR was correlated with longer OS for cancer.
format Online
Article
Text
id pubmed-8986630
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-89866302022-04-13 Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors Zhao, Lijun Li, Yang Jiang, Ning Song, Xue Xu, Jianhua Zhu, Xiangzhi Chen, Cheng Kong, Cheng Wang, Xiaohua Zong, Dan Li, Luan Han, Cen Yin, Li He, Xia J Immunother Clinical Studies Some patients with cancer treated with programmed death 1 (PD-1) inhibitors experience immune-related severe adverse events (ir-SAEs), however, predictors are limited. The objective was to identify clinicopathologic features that may be associated with a higher ir-SAE risk. This was a nested case-control study. After screening a total of 832 PD-1 inhibitor-treated patients, we identified 42 ir-SAE cases. According to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, ir-SAEs were defined as grade ≥3 toxic effects associated with immunotherapy. A total of 126 controls were matched. The crude and adjusted risks of ir-SAEs were estimated by odds ratio (ORs) and 95% CIs using multivariate logistic regression models. Baseline neutrophil-to-lymphocyte ratio (NLR) [per SD increment-adjusted (aOR): 1.16], lactate dehydrogenase (LDH) ≥245 U/L (aOR: 2.39), and antibiotic exposure (aOR: 4.39) were associated with a higher risk of ir-SAEs. When NLR was categorized in 3 groups, significantly higher risks of ir-SAEs (aOR: 4.95) were found in participants in group 3 (>6) than in those in group 1 (<3). Furthermore, NLR (per SD increment-adjusted hazard ratio:1.08) were also significantly associated with shorter overall survival (OS). Baseline LDH ≥245 U/L and antibiotic exposure were no significant association with OS. In conclusion, ir-SAEs were associated between baseline NLR, LDH ≥245 U/L and antibiotic exposure. Lower NLR was correlated with longer OS for cancer. Lippincott Williams & Wilkins 2022-05 2022-03-07 /pmc/articles/PMC8986630/ /pubmed/35250004 http://dx.doi.org/10.1097/CJI.0000000000000415 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Clinical Studies
Zhao, Lijun
Li, Yang
Jiang, Ning
Song, Xue
Xu, Jianhua
Zhu, Xiangzhi
Chen, Cheng
Kong, Cheng
Wang, Xiaohua
Zong, Dan
Li, Luan
Han, Cen
Yin, Li
He, Xia
Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
title Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
title_full Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
title_fullStr Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
title_full_unstemmed Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
title_short Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
title_sort association of blood biochemical indexes and antibiotic exposure with severe immune-related adverse events in patients with advanced cancers receiving pd-1 inhibitors
topic Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986630/
https://www.ncbi.nlm.nih.gov/pubmed/35250004
http://dx.doi.org/10.1097/CJI.0000000000000415
work_keys_str_mv AT zhaolijun associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT liyang associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT jiangning associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT songxue associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT xujianhua associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT zhuxiangzhi associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT chencheng associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT kongcheng associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT wangxiaohua associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT zongdan associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT liluan associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT hancen associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT yinli associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors
AT hexia associationofbloodbiochemicalindexesandantibioticexposurewithsevereimmunerelatedadverseeventsinpatientswithadvancedcancersreceivingpd1inhibitors